7
.
effective
dates
the
agency
is
proposing
to
make
any
final
rule
that
may
issue
based
upon
this
proposal
become
effective
180
days
after
its
publication
in
the
federal
register
.
.
fda
is
requesting
comments
on
this
effective
date
.
in
general
,
costs
of
compliance
for
labeling
and
other
requirements
are
less
if
longer
compliance
periods
are
provided
because
firms
can
incorporate
mandatory
changes
to
product
,
labeling
,
and
packaging
with
regularly
scheduled
changes
.
fda
requests
information
on
the
ability
of
manufacturers
of
products
that
contain
30
mg
or
more
iron
per
dosage
unit
to
convert
their
packaging
within
the
suggested
compliance
period
.
c
.
regulatory
flexibility
the
regulatory
flexibility
act
requires
analyzing
options
for
regulatory
relief
for
small
businesses
when
possible
.
fda
is
not
aware
that
any
small
businesses
will
be
affected
by
this
proposed
rule
.
therefore
,
fda
tentatively
concludes
that
this
proposed
rule
will
not
result
in
a
significant
burden
on
small
businesses
.
fda
requests
comments
on
any
potential
adverse
effect
on
small
businesses
.
d
.
summary
fda
has
examined
the
impact
of
the
proposed
rule
in
accordance
with
executive
order
12866
and
has
determined
that
it
is
not
an
economically
significant
rule
.
the
rule
will
result
in
total
costs
of
approximately
$
53
million
and
discounted
benefits
of
between
$
315
million
and
$
653
million
over
the
next
20
years
(
discounted
at
7
percent
.
fda
has
also
examined
the
impact
of
this
proposed
rule
on
small
businesses
in
accordance
with
the
regulatory
flexibility
act
.
fda
is
unaware
of
any
ironcontaining
iron
containing
products
manufactured
by
small
businesses
.
therefore
,
fda
has
determined
that
this
rule
will
not
result
in
a
significant
burden
on
small
businesses
.
vii
.
effective
date
the
agency
is
proposing
to
make
any
final
rule
that
may
issue
based
upon
this
proposal
became
effective
180
days
after
its
publication
in
the
federal
register
.
.
the
agency
is
requesting
comments
on
the
proposed
effective
date
.
all
comments
concerning
the
effective
date
should
be
accompanied
by
data
to
support
or
justify
any
change
in
the
proposed
effective
date
.
viii
.
comments
the
agencys
intention
in
proposing
this
action
is
to
reduce
the
incidence
of
pediatric
iron
poisonings
from
ingestion
of
ironcontaining
iron
containing
supplements
and
drug
products
.
fda
has
examined
all
relevant
information
available
to
the
agency
.
the
agency
requests
comments
on
this
proposed
action
and
is
particularly
interested
in
receiving
comments
that
bear
on
the
effectiveness
of
the
proposed
action
to
reduce
the
incidence
of
pediatric
iron
poisoning
.
interested
persons
may
,
on
or
before
12/20/1994
,
submit
to
the
dockets
management
branch
(
address
above
)
written
comments
regarding
this
proposal
.
two
copies
of
any
comments
are
to
be
submitted
,
except
that
individuals
may
submit
one
copy
.
comments
are
to
be
identified
with
the
docket
number
found
in
brackets
in
the
heading
of
this
document
.
received
comments
may
be
seen
in
the
office
above
between
9
am
.
and
4
pm
,
monday
through
friday
.
ix
.
references
the
following
references
have
been
placed
on
display
in
the
dockets
management
branch
(
address
above
)
and
may
be
seen
by
interested
persons
between
9
am
.
and
4
pm
,
monday
through
friday
.
1
.
us
.
consumer
product
safety
commission
,
`
pediatric
iron
poisonings
and
fatalities
'
p
.
3
,
05/19/1994
.
2
.
`
assessment
of
the
iron
nutritional
status
of
the
us
.
population
based
on
data
collected
in
the
second
national
health
and
nutrition
examination
survey
,
19761980
'
federation
of
american
societies
for
experimental
biology
,
life
sciences
research
office
,
bethesda
,
md
(
under
contract
to
fda
,
contract
no
.
223832384
,
08/19/1984
.
3
.
subcommittee
on
the
10th
edition
of
the
rdas
,
food
and
nutrition
board
,
commission
on
life
sciences
,
national
research
council
,
`
recommended
dietary
allowances
,
10th
ed
'
washington
,
dc
,
national
academy
press
,
pp
.
195205
,
1989
.
4
.
dawson
,
e
.
b
,
w
.
j
.
mcganity
,
`
protection
of
maternal
iron
stores
in
pregnancy
'
the
journal
of
reproductive
medicine
,
,
32478487
,
1987
.
5
.
committee
on
the
prevention
,
detection
,
and
management
of
iron
deficiency
anemia
among
us
.
children
and
women
of
childbearing
age
,
food
and
nutrition
board
,
institute
of
medicine
,
`
iron
deficiency
anemia
:
recommended
guidelines
for
the
prevention
,
detection
,
and
management
among
us
.
children
and
women
of
childbearing
age
'
by
earl
r
.
and
c
.
e
.
woteki
,
(
editors
)
national
academy
press
,
washington
,
dc
,
pp
.
1718
,
1993
.
6
.
`
iron
'
in
rudolphs
pediatrics
,
,
a
.
rudolph
,
jie
.
hoffman
,
c
.
d
.
rudolph
,
editors
;
appleton
&
amp
;
lange
,
norwalk
,
ct
,
19th
ed
,
p
.
806
,
1991
.
7
.
`
iron
'
in
nelson
textbook
of
pediatrics
,
,
by
r
.
e
.
behrman
,
r
.
m
.
kliegman
,
w
.
e
.
nelson
,
and
v
.
c
.
vaughan
(
editors
,
wb
.
saunders
co
,
philadelphia
,
pa
,
14th
ed
,
pp
.
17801781
,
1992
.
8
.
`
iron
'
in
manual
of
toxicology
emergencies
,
,
noji
,
k
.
(
editor
,
by
year
book
medical
publishers
,
inc
,
pp
.
496506
,
1989
.
9
.
`
hematopoietic
agents
:
growth
factors
,
minerals
,
and
vitamins
'
in
the
pharmacological
basis
of
therapeutics
,
,
edited
by
a
.
g
.
gilman
,
t
.
w
.
rall
,
a
.
s
.
nies
,
p
.
taylor
(
editors
,
pergamon
press
,
elmsford
,
new
york
,
8th
ed
,
pp
.
1291
,
1990
.
10
.
troendle
,
g
,
fda
memorandum
,
07/12/1994
.
11
.
temeck
,
j
,
fda
memorandum
,
08/10/1994
.
12
.
american
association
of
poison
control
center
,
inc
,
petition
to
fda
,
91p0186/cp1
,
1991
.
13
.
attorneys
general
petition
to
fda
,
93p0306/cp1
,
1993
.
14
.
litovitz
,
tl
,
tg
.
martin
,
b
.
schmitz
,
`
1986
annual
report
of
the
american
association
of
poison
control
centers
national
data
collection
system
'
american
journal
of
emergency
medicine
,
,
5405445
,
1987
.
<
text
>
